OncoMatch/Clinical Trials/NCT03750513
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Is NCT03750513 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for anaplastic ependymoma.
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE II, WHO GRADE III (WHO)
Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
Performance status
LANSKY 50–100
Demographics
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03750513 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage WHO GRADE II or WHO GRADE III is required.
Is there an age limit?
Yes. Patients must be 22 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages